Research ExplorerPublicationsDesigner Drugs for Designer Receptors: Unlocking the Transla...

Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics

Standard

Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics. / Yizhar, Ofer; Wiegert, J Simon.

In: TRENDS PHARMACOL SCI, Vol. 40, No. 6, 06.2019, p. 362-364.

Research output: SCORING: Contribution to journal › Other (editorial matter etc.) › Research

Harvard

Yizhar, O & Wiegert, JS 2019, 'Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics', TRENDS PHARMACOL SCI, vol. 40, no. 6, pp. 362-364. https://doi.org/10.1016/j.tips.2019.04.010

APA

Yizhar, O., & Wiegert, J. S. (2019). Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics. TRENDS PHARMACOL SCI, 40(6), 362-364. https://doi.org/10.1016/j.tips.2019.04.010

Vancouver

Yizhar O, Wiegert JS. Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics. TRENDS PHARMACOL SCI. 2019 Jun;40(6):362-364. https://doi.org/10.1016/j.tips.2019.04.010

Bibtex

@article{538488bb34b0496bb90009f1d6133f90,
title = "Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics",
abstract = "Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364:eaav5282) describes the coevolution of highly potent actuator-effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.",
author = "Ofer Yizhar and Wiegert, {J Simon}",
note = "Editorial Material",
year = "2019",
month = jun,
doi = "10.1016/j.tips.2019.04.010",
language = "English",
volume = "40",
pages = "362--364",
journal = "TRENDS PHARMACOL SCI",
issn = "0165-6147",
publisher = "Elsevier Limited",
number = "6",

}

RIS

TY - JOUR

T1 - Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics

AU - Yizhar, Ofer

AU - Wiegert, J Simon

N1 - Editorial Material

PY - 2019/6

Y1 - 2019/6

N2 - Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364:eaav5282) describes the coevolution of highly potent actuator-effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.

AB - Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364:eaav5282) describes the coevolution of highly potent actuator-effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.

U2 - 10.1016/j.tips.2019.04.010

DO - 10.1016/j.tips.2019.04.010

M3 - Other (editorial matter etc.)

C2 - 31072638

VL - 40

SP - 362

EP - 364

JO - TRENDS PHARMACOL SCI

JF - TRENDS PHARMACOL SCI

SN - 0165-6147

IS - 6

ER -